Correcting iron deficiency with Vifor Pharma’s Ferinject can improve renal function in chronic heart failure patients, according to a subanalysis study.
The study indicated that the difference between Ferinject and placebo groups is statistically significant with an increase in the estimated glomerular filtration rate.
The large, multi-centre, randomised, double-blind, placebo-controlled phase III study involved 459 patients with chronic heart failure in 75 sites worldwide.
Vifor Pharma is already either planning to conduct or currently conducting trials with the drug in chronic kidney disease, oncology, gastroenterology and gynaecology.
Kidney dysfunction complicates the course of chronic heart failure, increasing the severity of symptoms and the risk of hospitalisation and death.
